PTC Therapeutics CEO Sells Shares to Cover Tax Obligations
| Reporter Name | Klein Matthew B. |
| Relationship | CHIEF EXECUTIVE OFFICER |
| Type | Sell |
| Amount | $83,668 |
| SEC Filing | Form 4 |
Matthew B. Klein, Chief Executive Officer and Director of PTC Therapeutics, sold 3,361 shares of common stock on April 19, 2024, at a price of $24.894 per share, totaling $83,668. This sale was part of an automatic transaction to satisfy tax withholding obligations related to the vesting of restricted stock units. Following this transaction, Klein directly owns 225,807 shares of PTC Therapeutics.
SEC Filing: PTC THERAPEUTICS, INC. [ PTCT ] - Form 4 - Apr. 22, 2024